BridgeMD
Acute Subcutaneous Semaglutide in Acute Ischemic Stroke (ASSET Trial)
EU CTIS ID: 2022-501072-25-02
What this study is testing
To determine safety and efficacy of administering subcutaneous semaglutide in the acute phase after an ischemic stroke
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male and female patients (≥ 18 years) at the time of signed informed consent/proxy consent
- Acute ischemic stroke with disabling neurological deficits (defined as an impairment of one or more of the following: language, motor function, cognition, gaze, vision, neglect, or ataxia)
- Onset/last seen well to randomization < 4.5 hours, or DWI-FLAIR mismatch on MRI in patients with unknown time of onset and < 4,5 hours since symptoms were acknowledged
- None to moderate disability in daily living before symptom onset (pre-stroke modified Rankin Scale 0-3)
You likely can't join if
- Diabetes (known) or plasma/point of care test-glucose >11.1 mmol/L at admission
- BMI< 22
- History of pancreatitis, medullary thyroid carcinoma
- Predisposition or known Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Short remaining life expectancy (< 12months) and/or severe neurodegenerative disease
- Pregnancy or planned pregnancy within 12 months or breastfeeding
See the full eligibility criteria
- Male and female patients (≥ 18 years) at the time of signed informed consent/proxy consent
- Acute ischemic stroke with disabling neurological deficits (defined as an impairment of one or more of the following: language, motor function, cognition, gaze, vision, neglect, or ataxia)
- Onset/last seen well to randomization < 4.5 hours, or DWI-FLAIR mismatch on MRI in patients with unknown time of onset and < 4,5 hours since symptoms were acknowledged
- None to moderate disability in daily living before symptom onset (pre-stroke modified Rankin Scale 0-3)
- Diabetes (known) or plasma/point of care test-glucose >11.1 mmol/L at admission
- BMI< 22
- History of pancreatitis, medullary thyroid carcinoma
- Predisposition or known Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Short remaining life expectancy (< 12months) and/or severe neurodegenerative disease
- Pregnancy or planned pregnancy within 12 months or breastfeeding
- History of renal impairment (estimated glomerular filtration rate (eGFR) value of <30 mL/min/1.73 m2)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.